OBJECTIVES:
We
assessed hepatitis B virus (HBV) status in children born to HIV/HBV coinfected
women with large access to antiretroviral therapy.
METHODS:
All HIV/HBV coinfected pregnant women from 01 January 2000 to
01 January 2012 were included in the retrospective study (NCT02044068).
Antiretroviral therapy during pregnancy and injection of HBV
immunoglobulin/vaccine to newborns was recorded. We assessed HBV status of
children aged at least 2 years.
RESULTS:
Twenty-one
women (35 children) were studied. Twenty-six children (74%) had HBsAb: 22 had
received immunoglobulin and 24 had received a complete vaccine (with
immunoglobulin in 21 cases); their mothers had been administered lamivudine or
tenofovir/emtricitabine during eight and nine pregnancies, respectively. Eight
children (23%) were negative for HBsAg, HBsAb, and HBcAb: four (11.5%) had
received immunoglobulin and a complete vaccine; in two children, it was not
known whether they had received an immunoglobulin injection; in one child, the
vaccine was incomplete; and in the last one, it was not known whether he had
received immunoglobulin/vaccine. Their mothers had been administered lamivudine
or tenofovir/emtricitabine during five and two pregnancies, respectively. No
infant has chronic HBV infection (HBsAg) after prenatal mothers' antiretroviral
therapy combined with a complete postnatal HBV protection. One child had HBcAb
and HBsAb: it was not known whether she had received an immunoglobulin
injection; the vaccine was incomplete. The mother had been administered
lamivudine during the last trimester of pregnancy.
CONCLUSION:
Antiretroviral
therapy in HBV/HIV coinfected women following current national HBV guidelines
may prevent mother-to-child-transmission of HBV. Negativity of surrogate
markers of vaccine-induced protection is frequent; large studies on long-term
protection are needed.
By: Sellier PO1, Schnepf N, Amarsy R, Maylin S, Lopes A, Mazeron MC, Flateau C, Morgand M, Ciraru-Vigneron N, Berthe A, Simoneau G, Evans J, Souak S,Matheron S, Benifla JL, Simon F, Bergmann JF.
1aDepartment of Internal Medicine A bDepartment of
Virology cDepartment of Microbiology dDepartment of Obstetrics ePharmacy,
AP-HP, Saint-Louis-Lariboisière Hospital fInfectious Diseases Department,
AP-HP, Bichat - Claude Bernard Hospital, HUPNVS; Paris-Diderot, Sorbonne
Paris-Cité University, Paris, France.
No comments:
Post a Comment